Wird geladen...
Durvalumab in NSCLC: latest evidence and clinical potential
Advances in immunotherapy have led to radical improvements in outcomes, including overall survival, such as in non-small cell lung cancer (NSCLC) patients with metastatic disease treated with immune checkpoint inhibitors. More recently, promising results have been obtained in earlier disease setting...
Gespeichert in:
| Veröffentlicht in: | Ther Adv Med Oncol |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
SAGE Publications
2018
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6187424/ https://ncbi.nlm.nih.gov/pubmed/30344651 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835918804151 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|